rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2010-6-4-558-564rpcardio-888Research ArticleCURRENT QUESTIONS OF CLINICAL PHARMACOLOGYАКТУАЛЬНЫЕ ВОПРОСЫ КЛИНИЧЕСКОЙ ФАРМАКОЛОГИИPOSITIONS OF CALCIUM CHANNEL BLOCKER LERCANIDIPINE ACCORDING TO EVIDENCE BASED CARDIOLOGYПОЗИЦИИ АНТАГОНИСТА КАЛЬЦИЯ ЛЕРКАНИДИПИНА ПО ДАННЫМ ДОКАЗАТЕЛЬНОЙ КАРДИОЛОГИИЛукинаЮ. В.LukinaYu. V.

д.м.н., профессор, руководитель отдела профилактической фармакотерапии

профессор кафедры доказательной медицины

101990 Москва, Петроверигский пер., 10

119992, Москва, ул. Трубецкая, д. 8, стр. 1

Petroverigsky per. 10, Moscow, 101990

Chair of Evidence Based Medicine

Trubetskaya ul. 8, stroen. 1, Moscow, 119992 

jlukina@gnicpm.ruМарцевичС. Ю.MartsevichS. Yu.

к.м.н., ст.н.с. отдела профилактической фармакотерапии

ассистент кафедры доказательной медицины

101990 Москва, Петроверигский пер., 10

119992, Москва, ул. Трубецкая, д. 8, стр. 1

Petroverigsky per. 10, Moscow, 101990

Chair of Evidence Based Medicine

Trubetskaya ul. 8, stroen. 1, Moscow, 119992 

Государственный научно-исследовательский центр профилактической медицины, Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияState Research Center for Preventive Medicine, I.M. Setchenov First Moscow State Medical UniversityRussian Federation20101901201664558564Copyright © Lukina Y.V., Martsevich S.Y., 20162016Лукина Ю.В., Марцевич С.Ю.Lukina Y.V., Martsevich S.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/888

Data of evidence based cardiology including results of international clinical trials on efficacy and safety of the modern calcium channel blocker (CCB), lercanidipine, are presented. Results of these trials show the firm position of lercanidipine in the modern cardiology and confirm that treatment with lercanidipine leads to significant reduction of systolic and diastolic blood pressure (BP) with no effect on heart rate (HR). Peripheral edema (the common side effect of CCBs) occurs rarer with lercanidipine treatment than this with any other CCB treatment. Lercanidipine can be recommended to patients with concomitant diseases due to its additional features.

Представлены данные доказательной кардиологии по результатам зарубежных исследований, в которых изучались эффективность и безопасность современного антагониста кальция (АК) лерканидипина. Результаты представленных исследований демонстрируют устойчивые позиции лерканидипина в современной кардиологии и свидетельствуют, что лечение лерканидипином приводит к выраженному снижению систолического и диастолического артериального давления без существенного влияния на частоту сердечных сокращений. В процессе лечения лерканидипином возникновение периферических отеков — основной побочной реакции, встречающейся при лечении АК, — наблюдается значительно реже, чем при использовании других представителей данного класса препаратов. Дополнительные свойства лерканидипина позволяют рекомендовать применение данного АК при сочетанной патологии.

лерканидипинантагонисты кальциярандомизированные клинические исследованияартериальная гипертонияlercanidipinecalcium channel blockersrandomized clinical trialsarterial hypertensionReferencesМетелица В.И. Справочник по клинической фармакологии сердечно-сосудистых лекарственных средств. М.: МИА; 2005.Метелица В.И. Справочник по клинической фармакологии сердечно-сосудистых лекарственных средств. М.: МИА; 2005.Herbette L.G., Vecchiarelli M., Sartani A., Leonardi A. Lercanidipine: Short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties. Blood Press Suppl 1998;2:10-7.Herbette L.G., Vecchiarelli M., Sartani A., Leonardi A. Lercanidipine: Short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties. Blood Press Suppl 1998;2:10-7.ШпигельА.С.Доказательная медицина. Перспективыдля гомотоксикологии. М.:Арнебия; 2004.ШпигельА.С.Доказательная медицина. Перспективыдля гомотоксикологии. М.:Арнебия; 2004.Barchielli M.,Dolfini E., Farina P. et al. Clinical pharmacokinetics oflercanidipine.J Cardiovasc Pharmacol 1997;29 Suppl 2:S1–15.Barchielli M.,Dolfini E., Farina P. et al. Clinical pharmacokinetics oflercanidipine.J Cardiovasc Pharmacol 1997;29 Suppl 2:S1–15.Leonardi A., Poggesi E., Taddei C. et al. In vitro calcium antagonist activity of lercanidipine and its enantiomers. J Cardiovasc Pharmacol 1997;29 Suppl 1:S10–S18.Leonardi A., Poggesi E., Taddei C. et al. In vitro calcium antagonist activity of lercanidipine and its enantiomers. J Cardiovasc Pharmacol 1997;29 Suppl 1:S10–S18.Angelico P., Guarneri L., Leonardi A., Testa R. Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues. J Pharm Pharmacol 1999;51(6): 709–14.Angelico P., Guarneri L., Leonardi A., Testa R. Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues. J Pharm Pharmacol 1999;51(6): 709–14.Herbette L.G., Vecchiarelli M., Leonardi A. Lercanidipine: short plasma half-life, long du￾ration of action. J Cardiovasc Pharmacol 1997;29 Suppl 1:S19–24.Herbette L.G., Vecchiarelli M., Leonardi A. Lercanidipine: short plasma half-life, long du￾ration of action. J Cardiovasc Pharmacol 1997;29 Suppl 1:S19–24.Bianchi G., Passoni A., Griffini P.L. Effects of a new calcium antagonist, Rec 15/2375, on cardiac contractility of conscious rabbits. Pharmacol Res 1989;21(2):193-200.Bianchi G., Passoni A., Griffini P.L. Effects of a new calcium antagonist, Rec 15/2375, on cardiac contractility of conscious rabbits. Pharmacol Res 1989;21(2):193-200.De Giorgio L.A., Orlandini F., Malasoma P., Zappa A. Double-blind crossover study of lercanidipine versus amlodipine in the treatment of mild-to-moderate essential hypertension. Curr Ther Res 1999;60(10):511-20.De Giorgio L.A., Orlandini F., Malasoma P., Zappa A. Double-blind crossover study of lercanidipine versus amlodipine in the treatment of mild-to-moderate essential hypertension. Curr Ther Res 1999;60(10):511-20.Cafiero M., Giasi M. Long-term (12-month) treatment with lercanidipine in patients with mild to moderate hypertension. J Cardiovasc Pharmacol 1997;29 Suppl 2:S45–49.Cafiero M., Giasi M. Long-term (12-month) treatment with lercanidipine in patients with mild to moderate hypertension. J Cardiovasc Pharmacol 1997;29 Suppl 2:S45–49.Barrios V., Navarro A., Esteras A. et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Eficacia de Lercanidipino y su Perfil de Seguridad. Blood Press 2002;11(2):95–100.Barrios V., Navarro A., Esteras A. et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Eficacia de Lercanidipino y su Perfil de Seguridad. Blood Press 2002;11(2):95–100.McClellan K.J., Jarvis B. Lercanidipine. A review of its use in hypertension. Drugs 2000;60(5):1123-40.McClellan K.J., Jarvis B. Lercanidipine. A review of its use in hypertension. Drugs 2000;60(5):1123-40.Testa R., Leonardi A., Tajana A. et al. Lercanidipine (Rec 15/2375): a novel 1,4–dihydropyridine calcium antagonist for hypertension. Cardiovasc Drug Rev 1997;15(3): 187-219.Testa R., Leonardi A., Tajana A. et al. Lercanidipine (Rec 15/2375): a novel 1,4–dihydropyridine calcium antagonist for hypertension. Cardiovasc Drug Rev 1997;15(3): 187-219.Policicchio D., Magliocca R., Malliani A. Efficacy and tolerability of lercanidipine in patients with mild to moderate essential hypertension: a comparative study with slow-release nifedipine. J Cardiovasc Pharmacol 1997;29 Suppl 2:S31-S35.Policicchio D., Magliocca R., Malliani A. Efficacy and tolerability of lercanidipine in patients with mild to moderate essential hypertension: a comparative study with slow-release nifedipine. J Cardiovasc Pharmacol 1997;29 Suppl 2:S31-S35.Rengo F., Romis L. Activity of lercanidipine in double-blind comparison with nitrendipine in combination treatment of patients with resistant essential hypertension.J Cardiovasc Pharmacol 1997;29 Suppl 2:S54-58.Rengo F., Romis L. Activity of lercanidipine in double-blind comparison with nitrendipine in combination treatment of patients with resistant essential hypertension.J Cardiovasc Pharmacol 1997;29 Suppl 2:S54-58.Morisco C., Trimarco B. Efficacy and tolerability oflercanidipine in comparison and in combination with atenolol in patients with mild to moderate hypertension in double–blind controlled study. J Cardiovasc Pharmacol 1997;29 Suppl 2:S26-S30.Morisco C., Trimarco B. Efficacy and tolerability oflercanidipine in comparison and in combination with atenolol in patients with mild to moderate hypertension in double–blind controlled study. J Cardiovasc Pharmacol 1997;29 Suppl 2:S26-S30.Sangiorgi B.G., Putignano E.,Calcara L., BarbagalloM. Efficacy and tolerability oflercanidipine vs. captopril in patients with mild to moderate hypertension in a double–blind controlled study. J Cardiovasc Pharmacol 1997;29 Suppl 2:S36-S39.Sangiorgi B.G., Putignano E.,Calcara L., BarbagalloM. Efficacy and tolerability oflercanidipine vs. captopril in patients with mild to moderate hypertension in a double–blind controlled study. J Cardiovasc Pharmacol 1997;29 Suppl 2:S36-S39.Sanchez A., Sayans R., Alvarez J.L. et al. Left ventricular hypertrophy regression after a short antihypertensive treatment with lercanidipine vs. enalapril [abstract no. 12]. Fourth European Meeting on Calcium Antagonists; 1999 Oct 27–29; Amsterdam.Sanchez A., Sayans R., Alvarez J.L. et al. Left ventricular hypertrophy regression after a short antihypertensive treatment with lercanidipine vs. enalapril [abstract no. 12]. Fourth European Meeting on Calcium Antagonists; 1999 Oct 27–29; Amsterdam.Fogari R., Mugellini A., Corradi L. et al. Efficacy of lercanidipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients [abstract].JHypertens 2000; 18 (Suppl 2):S65.Fogari R., Mugellini A., Corradi L. et al. Efficacy of lercanidipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients [abstract].JHypertens 2000; 18 (Suppl 2):S65.Aranda P., Aranda F.T., Bianchi J.L. et al. Therapeutic efficacy and tolerability of lercanidipine versus candesartan, alone or in combination, in mild-moderate essential hypertensives [abstract]. J Hypertens 2000;18 Suppl 2:S152.Aranda P., Aranda F.T., Bianchi J.L. et al. Therapeutic efficacy and tolerability of lercanidipine versus candesartan, alone or in combination, in mild-moderate essential hypertensives [abstract]. J Hypertens 2000;18 Suppl 2:S152.Fogari R., Malamani G.D., Zoppi A. et al. Comparative effect of lercanidipine and nifedipine gastrointestinaltherapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: a double-blind,randomized, parallel-group study. Curr Ther Res 2000;61(12):850-62.Fogari R., Malamani G.D., Zoppi A. et al. Comparative effect of lercanidipine and nifedipine gastrointestinaltherapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: a double-blind,randomized, parallel-group study. Curr Ther Res 2000;61(12):850-62.Romito R., Pansini M.I., Perticone F. et al. Comparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the LErcanidipine in ADults (LEAD) study. J Clin Hypertens (Greenwich) 2003;5(4):249-53.Romito R., Pansini M.I., Perticone F. et al. Comparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the LErcanidipine in ADults (LEAD) study. J Clin Hypertens (Greenwich) 2003;5(4):249-53.Borghi C., Prandin M.G., Dormi A. The use of lercanidipine can improve the individual tolerability to dihydropyridine calcium blockers in hypertensive patients [abstract]. J Hypertens 2000;18 Suppl 2:S155.Borghi C., Prandin M.G., Dormi A. The use of lercanidipine can improve the individual tolerability to dihydropyridine calcium blockers in hypertensive patients [abstract]. J Hypertens 2000;18 Suppl 2:S155.Ninci M.A., Magliocca R., Malliani A. Efficacy and tolerability of lercanidipine in elderly patients with mild to moderate hypertension in a placebo-controlled, double-blind study. J Cardiovasc Pharmacol 1997;29 Suppl 2: S40–S44.Ninci M.A., Magliocca R., Malliani A. Efficacy and tolerability of lercanidipine in elderly patients with mild to moderate hypertension in a placebo-controlled, double-blind study. J Cardiovasc Pharmacol 1997;29 Suppl 2: S40–S44.Omboni S., Zanchetti A. Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. Multicenter Study Investigators. J Hypertens 1998;16(12 Pt 1):1831–8.Omboni S., Zanchetti A. Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. Multicenter Study Investigators. J Hypertens 1998;16(12 Pt 1):1831–8.Cherubini A., Fabris F., Ferrari E. et al. Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients:the ELderly and LErcanidipine (ELLE) study.Arch Gerontol Geriatr 2003;37(3):203-12.Cherubini A., Fabris F., Ferrari E. et al. Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients:the ELderly and LErcanidipine (ELLE) study.Arch Gerontol Geriatr 2003;37(3):203-12.Белоусов Ю.Б., Леонова М.В. Антагонисты кальция пролонгированного действия и сердечно-сосудистая заболеваемость: новые данные доказательной медицины. Кардиология 2001;(4):87-93.Белоусов Ю.Б., Леонова М.В. Антагонисты кальция пролонгированного действия и сердечно-сосудистая заболеваемость: новые данные доказательной медицины. Кардиология 2001;(4):87-93.Wu J.R., Liou S.F., Lin S.W. et al. Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellular reactive oxygen species and inactivating Ras-ERK1/2 signaling. Pharmacol Res 2009;59(1):48-56.Wu J.R., Liou S.F., Lin S.W. et al. Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellular reactive oxygen species and inactivating Ras-ERK1/2 signaling. Pharmacol Res 2009;59(1):48-56.Corsini A., Bonfatti M., Quarato P. et al. Effect of the new calcium antagonist Iercanidipine and its enantiomers on the migration and proliferation of arterial myocytes. J Cardiovasc Pharmacol 1996;28(5):687-94.Corsini A., Bonfatti M., Quarato P. et al. Effect of the new calcium antagonist Iercanidipine and its enantiomers on the migration and proliferation of arterial myocytes. J Cardiovasc Pharmacol 1996;28(5):687-94.Grossman E., Messerli F.H. Calcium antagonists. Prog Cardiovasc Dis 2004;47(1): 34-57.Grossman E., Messerli F.H. Calcium antagonists. Prog Cardiovasc Dis 2004;47(1): 34-57.Specchia G., Saccaggi S.P., Ghezzi C. Cardiovascular safety of lercanidipine in patients with angina pectoris: a review of six randomized clinical trials. Curr Ther Res 2001;62(1): 3–15.Specchia G., Saccaggi S.P., Ghezzi C. Cardiovascular safety of lercanidipine in patients with angina pectoris: a review of six randomized clinical trials. Curr Ther Res 2001;62(1): 3–15.Acanfora D., Gheorgiade M., Rotiroti D. et al. Acute dose-response, double-blind, placebo-controlled pilot study of lercanidipine in patients with angina pectoris. Curr Ther Res 2000;61(5):255-65.Acanfora D., Gheorgiade M., Rotiroti D. et al. Acute dose-response, double-blind, placebo-controlled pilot study of lercanidipine in patients with angina pectoris. Curr Ther Res 2000;61(5):255-65.Leenen F.H. Dihydropyridine calcium antagonists and sympathetic activity: relevance to cardiovascular morbidity and mortality. In: Epstein M, editor. Calcium Antagonists in Clinical Medicine. 2nd ed. Philadelphia: Hanley & Belfus; 1998. P.527–52.Leenen F.H. Dihydropyridine calcium antagonists and sympathetic activity: relevance to cardiovascular morbidity and mortality. In: Epstein M, editor. Calcium Antagonists in Clinical Medicine. 2nd ed. Philadelphia: Hanley & Belfus; 1998. P.527–52.Epstein M. Safety of calcium antagonists as antihypertensive agents: an update. In: Epstein M (ed). Calcium Antagonists in Clinical Medicine. 2nd ed. Philadelphia: Hanley & Belfus; 1998. P.553-71.Epstein M. Safety of calcium antagonists as antihypertensive agents: an update. In: Epstein M (ed). Calcium Antagonists in Clinical Medicine. 2nd ed. Philadelphia: Hanley & Belfus; 1998. P.553-71.Sabbatini M., Tomassoni D., Amenta P. Influence of treatment with Ca2+ antagonists on cerebral vasculature of spontaneously hypertensive rats. Mech Ageing Dev 2001;122(8):795-809.Sabbatini M., Tomassoni D., Amenta P. Influence of treatment with Ca2+ antagonists on cerebral vasculature of spontaneously hypertensive rats. Mech Ageing Dev 2001;122(8):795-809.Sabbatini M., Leonardi A., Testa R. et al. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 2000;35(3):775-9.Sabbatini M., Leonardi A., Testa R. et al. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 2000;35(3):775-9.Sabbatini M., Vitaioli L., Baldoni E. et al. Nephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive rats. J Pharmacol Exp Ther 2000;294(3):948-54.Sabbatini M., Vitaioli L., Baldoni E. et al. Nephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive rats. J Pharmacol Exp Ther 2000;294(3):948-54.Dalla Vestra M., Pozza G., Mosca A. et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria:DIAL study (diabete, ipertensione, albuminuria, lercanidipina).Diabetes Nutr Metab 2004;17(5):259-66.Dalla Vestra M., Pozza G., Mosca A. et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria:DIAL study (diabete, ipertensione, albuminuria, lercanidipina).Diabetes Nutr Metab 2004;17(5):259-66.Robles N.R., Ocon J., Gomez C.F. et al. Lercanidipine in Patients with Chronic Renal Failure: The ZAFRA study. Ren Fail 2005;27(1):73-80.Robles N.R., Ocon J., Gomez C.F. et al. Lercanidipine in Patients with Chronic Renal Failure: The ZAFRA study. Ren Fail 2005;27(1):73-80.Cesarone M.R., Incandela L., Ledda A. et al. Pressure and microcirculatory effects of treatment with lercanidipine in hypertensive patients and in vascular patients with hypertension. Angiology 2000;51(8 Pt 2):S53-63.Cesarone M.R., Incandela L., Ledda A. et al. Pressure and microcirculatory effects of treatment with lercanidipine in hypertensive patients and in vascular patients with hypertension. Angiology 2000;51(8 Pt 2):S53-63.Viviani G.L. Lercanidipine in type II diabetic patients with mild to moderate arterial hypertension. J Cardiovasc Pharmacol 2002;40(1):133-9.Viviani G.L. Lercanidipine in type II diabetic patients with mild to moderate arterial hypertension. J Cardiovasc Pharmacol 2002;40(1):133-9.

The authors declare that there are no conflicts of interest present.